Why the study?
Norovirus vaccine development has been delayed by an inadequate understanding of the role of norovirus diversity in immunity.
Identification of new antigenic sites on GII.4 noroviruses could facilitate early detection of pandemic variants and inform vaccine design.
May inform GII.4 norovirus vaccine strain selection; leaves open functional validation of antigenic impact.
Noroviruses are an important cause of viral gastroenteritis around the world. An obstacle delaying the development of norovirus vaccines is inadequate understanding of the role of norovirus diversity in immunity. Using a population genomics approach, we identified new residues on the viral capsid protein (VP1) from GII.4 noroviruses, the predominant genotype, that appear to be involved in the emergence and antigenic topology of GII.4 variants. Careful monitoring of the substitutions in those residues involved in the diversification and emergence of new viruses could help in the early detection of future novel variants with pandemic potential. Therefore, this novel information on the antigenic diversification could facilitate GII.4 norovirus vaccine design.
No takes yet. Share an insight, caveat, or question.
Tohma et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: